Inari Medical Announces Completion of Patient Enrollment in the FLARE Study for the Treatment of Pulmonary Embolism

IRVINE, CALIFORNIA – October 19, 2017 – Inari Medical, Inc., a privately held venture backed medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism (“VTE”), announced today it has completed enrollment of its Investigational Device Exemption (“IDE”) study. The FlowTriever Pulmonary Embolectomy Clinical Study (“FLARE”) study is designed to evaluate the safety and effectiveness of the FlowTriever Retrieval/Aspiration System for the treatment of pulmonary embolism.

+ Read More

Inari Medical Announces First Patient Treated with the ClotTriever™ Thrombectomy System; FDA 510(k) Clearance Received for Peripheral Thrombectomy

IRVINE, CALIFORNIA – April 10, 2017 – Inari Medical Inc., a venture capital backed medical device company focused on the interventional treatment of venous thrombus, announced the treatment of the first patient with its ClotTriever Thrombectomy System. The ClotTriever Thrombectomy System received 510(k) marketing clearance from the U.S. Food and Drug Administration on February 16 for the non-surgical removal of thrombus (blood clots) from the peripheral vasculature.

+ Read More

Inari Medical And Inceptus Medical Announce Receipt Of TCT Innovation Award

IRVINE, CALIFORNIA, November 23, 2015 – Inari Medical, Inc. and Inceptus Medical LLC announced today that the Inari FlowTriever® Retrieval /Aspiration System for thrombectomy received a 1st place Innovation Award at the 2015 Transcatheter Therapeutics (TCT) conference in San Francisco.

“We are pleased to have the FlowTriever thrombectomy system showcased at such a large and prestigious venue as TCT,” says Bill Hoffman, President and CEO of Inari. Bob Rosenbluth, President of Inceptus added, “We are proud to have Inari get this recognition at the largest medical device conference for interventional therapy. This is a nice honor as we initiate our pivotal trial to investigate the use of the FlowTriever specifically for the treatment of pulmonary embolism.”

+ Read More